GT Biopharma, Inc.
Hedge Funds Holdings
Last updated:
GT Biopharma, Inc.‘s stocks are currently a part of 20 hedge funds’ portfolios, which represents 100% of the total amount of its stocks outstanding. This makes up a total of 1.05M shares of GT Biopharma, Inc.. Compared to the previous quarter, the number fell by -83.41% or -5.29M shares fewer. As for the holding position changes, 35% (7) of current hedge fund investors increased the number of shares held, 10% (2) of current holders sold a part of the shares held, and 5% (1) closed the holdings completely. 2 hedge funds are new holders of GT Biopharma, Inc. stock in Q1 2023, it is 10% of total holders.
Hedge funds holding GT Biopharma (Q4 2017 – Q1 2023)
| Q4 2017 | 1 |
|---|---|
| Q1 2018 | 2 |
| Q2 2018 | 1 |
| Q3 2018 | 1 |
| Q4 2018 | 1 |
| Q1 2019 | 1 |
| Q2 2019 | 1 |
| Q3 2019 | 0 |
| Q1 2021 | 17 |
| Q2 2021 | 47 |
| Q3 2021 | 53 |
| Q4 2021 | 52 |
| Q1 2022 | 55 |
| Q2 2022 | 43 |
| Q3 2022 | 31 |
| Q4 2022 | 32 |
| Q1 2023 | 20 |
Hedge funds changes in GT Biopharma positions (Q4 2017 – Q1 2023)
| Q4 2017 | 1 | 0 | 0 | 0 | 0 |
|---|---|---|---|---|---|
| Q1 2018 | 1 | 0 | 0 | 0 | 1 |
| Q2 2018 | 0 | 0 | 0 | 0 | 1 |
| Q3 2018 | 0 | 0 | 1 | 0 | 0 |
| Q4 2018 | 0 | 1 | 0 | 0 | 0 |
| Q1 2019 | 0 | 0 | 0 | 0 | 1 |
| Q2 2019 | 0 | 0 | 0 | 0 | 1 |
| Q3 2019 | 0 | 0 | 0 | 1 | -1 |
| Q1 2021 | 17 | 0 | 0 | 0 | 0 |
| Q2 2021 | 34 | 7 | 4 | 4 | -2 |
| Q3 2021 | 15 | 13 | 17 | 9 | -1 |
| Q4 2021 | 10 | 23 | 6 | 11 | 2 |
| Q1 2022 | 10 | 6 | 27 | 7 | 5 |
| Q2 2022 | 4 | 11 | 18 | 14 | -4 |
| Q3 2022 | 2 | 5 | 14 | 15 | -5 |
| Q4 2022 | 9 | 9 | 5 | 7 | 2 |
| Q1 2023 | 2 | 7 | 2 | 1 | 8 |
Hedge funds changes in GT Biopharma stock options (Q4 2017 – Q1 2023)
| Q4 2017 | 0 | 0 |
|---|---|---|
| Q1 2018 | 0 | 0 |
| Q2 2018 | 0 | 0 |
| Q3 2018 | 0 | 0 |
| Q4 2018 | 0 | 0 |
| Q1 2019 | 0 | 0 |
| Q2 2019 | 0 | 0 |
| Q3 2019 | 0 | 0 |
| Q1 2021 | 0 | 0 |
| Q2 2021 | 9,000 | 0 |
| Q3 2021 | 553,000 | 925,000 |
| Q4 2021 | 334,000 | 239,000 |
| Q1 2022 | 156,000 | 135,000 |
| Q2 2022 | 78,000 | 2,000 |
| Q3 2022 | 0 | 0 |
| Q4 2022 | 0 | 0 |
| Q1 2023 | 0 | 0 |